Journal of Experimental & Clinical Cancer Research · 2023 · 14 citations · 16 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor ProgressionCancer Cell SignalingCancer ProgressionKidney CancerMicrorna-mediated RegulationOncogenic Signaling PathwaysRenal Cell CarcinomaCancer Signaling PathwaysLuciferase Reporter AssaysLuciferase ReportersMalignant ProgressionMicrorna In CancerMicrorna Regulation In CancerMicrorna-mediated OncogenesisMicrorna-mediated Pathway Regulation
BACKGROUND: Although the aberrant activation of NOTCH1 pathway causes a malignant progression of renal cell carcinoma (RCC), the precise molecular mechanisms behind the potential action of pro-oncogenic NOTCH1/HES1 axis remain elusive. Here, we examined the role of tumor suppressive miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC. METHODS: This study employed bioinformatics, xenotransplant mouse models, ChIP assay, luciferase reporter assay, functional experiments, real-time PCR and Western blot analysis to explore the mechanisms of miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC, and further explored miR-138-2-containing combination treatment strategies. RESULTS: There existed a positive correlation between down-regulation of miR-138 and the aberrant augmentation of NOTCH1/HES1 regulatory axis. Mechanistically, HES1 directly bound to miR-138-2 promoter region and thereby attenuated the transcription of miR-138-5p as well as miR-138-2-3p. Further analysis revealed that miR-138-5p as well as miR-138-2-3p synergistically impairs pro-oncogenic NOTCH1 pathway through the direct targeting of APH1A, MAML1 and NOTCH1. CONCLUSIONS: Collectively, our current study strongly suggests that miR-138-2 acts as a novel epigenetic regulator of pro-oncogenic NOTCH1 pathway, and that the potential feedback regulatory loop composed of HES1, miR-138-2 and NOTCH1 contributes to the malignant development of RCC. From the clinical point of view, this feedback regulatory loop might be a promising therapeutic target to treat the patients with RCC.
16
Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
Annika Fendler, Daniel Bauer, Jonas Busch et al. · Nature Communications · 2020 · 199 citations · Full text
Medicine, Cell Biology, Oncology +17